ArticleMolecular biology reports2025
Characterization and genome analysis of a novel lytic phage vB_ntSalS-cftriSP11 infecting Salmonella typhimurium.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comprehensive Characterization of a Novel Broad-Host-Range LyticAntibiotics (Basel, Switzerland) · 2026Article
- Unravelling the genomic and functional potential of bacteriophages against non-typhoidal Salmonella Enteritidis and Salmonella Typhimurium.Archives of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIn response to rising antibiotic resistance, bacteriophage application is gaining renewed attention, marking a paradigm shift in managing bacterial infections, especially foodborne pathogens. Non-typhoidal salmonellosis remains a major global health burden. In this context, a novel lytic bacteriophage targeting Salmonella typhimurium was isolated and characterized. METHODS AND
resultsA novel phage, vB_ntSalS-cftriSP11, targeting S. typhimurium, was isolated using spot and double agar overlay methods. One-step growth analysis showed a burst size of 146 ± 10 particles with a 20 min latency period. The phage exhibited a broad host range and stability across a wide pH and temperature range. Morphological and genomic analyses identified it as a member of Casjensviridae, with a 56,837 bp genome encoding 103 of 105 predicted ORFs linked to biological processes, cellular components, and molecular functions. Notably, no toxin genes, virulence factors, or antimicrobial resistance genes were detected in the genome. BLAST and phylogenetic analyses revealed high sequence similarity (97-98%) with known Salmonella phages 35, 37 and PK4. Functionally, the phage demonstrated strong anti-Salmonella activity, reducing biofilm biomass by 1.86-fold and 2.11-fold in 48- and 72-h-old biofilms, respectively, after 24 h of treatment. It also significantly decreased Salmonella counts on chicken breast samples at RT and 4 ℃ at MOI 1 compared to the culture control.
conclusionsThe Phage vB_ntSalS-cftriSP11 was identified as a stable, lytic bacteriophage with a broad host range and strong antibiofilm activity against S typhimurium. Its genetic safety profile and efficacy highlight its potential as a promising biocontrol agent against antibiotic-resistant Salmonella infections.
Indexed as
Identifiers
40783479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.